Brief: HUTCHMED (China) Announces NMPA Conditional Approval For ATLED In China
28/08/2026 07:20
BRIEF-HUTCHMED (China) Announces NMPA Conditional Approval For ATLED In China Aug 28 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
HUTCHMED CHINA LTD - NMPA APPROVAL FOR ATLED® (FANREGRATINIB) FOR ICC
HUTCHMED (CHINA) - ANNOUNCES NMPA CONDITIONAL APPROVAL FOR FANREGRATINIB (ATLED) IN CHINA
HUTCHMED (CHINA) - FANREGRATINIB TO BE MARKETED IN CHINA AS ATLED
Source text: ID:nRSb4949Sa
Further company coverage: 0013.HK
(((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation